

F-6824


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Walter MUELLER, et al.
Serial No. : 09/647,290
Filed : November 28, 2000
For : TRANSDERMAL THERAPEUTIC SYSTEM
WHICH CONTAINS A D2 AGONIST AND WHICH
IS PROVIDED FOR TREATING PARKINSONISM,
AND A METHOD FOR THE PRODUCTION
THEREOF
Group Art Unit : 1615
Examiner : Isis A. D. Ghali

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on April 22, 2003.

C. Bruce Hamburg
(Name)


(Signature)

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is an Information Disclosure Citation together
with copies of references referred to therein.

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900
5/6/03

04/29/2003 WABDELRI 00000144 101250 09647290
01 FC:1806 180.00 CH


It is hereby certified by the undersigned that no item of information cited in this Information Disclosure Citation was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information cited in this Information Disclosure Citation was known to any individual designated in §1.56(c) more than three months prior to the filing of this information disclosure statement.

Please charge the \$180.00 government fee to Deposit Account No. 10-1250. Also charge any fee deficiency or credit any overpayment to the same deposit account.

Respectfully submitted,

Jordan and Hamburg LLP

By


C. Bruce Hamburg
Reg. No. 22,389
Attorney for Applicants

Jordan and Hamburg LLP
122 East 42nd Street
New York, New York 10168
(212) 986-2340



RECEIVED

MAY 05 2003

F-6824

Form PTO-1449 (Rev. 7-80) 42-44F (F-49)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.: F-6824		Serial No. 09447020	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Walter MUELLER, et al.		Filing Date: November 28, 2000	
				Group: 1615			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
TRANSLATION KEY: * English Abstract. ^F Concise statement of relevance provided in foreign search report. ^C Concise statement of relevance provided in specification. ^S Concise statement of relevance provided in IDS. ^P Relevant portion of reference translated. ^O English abstract only - copy of reference in pct search.							
OTHER INFORMATION DISCLOSURE CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		3/14/1989 Abstract of "Microdialysis and Striatal dopamine release: stereoselective actions of the enantiomers of N-0437" W. Timmerman et al. Eur J. Pharmacol 143-150					
		8/18/1995 Abstract of "Development and validation of a gradient reversed-phase high-performance liquid chromatographic assay for S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (n-0923) from a transdermal delivery system" D.L. Walters et al. J. Chromatogr. B. Biomed Appl. 299-307					
		12/1990 Abstract of "Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model" Tepper P.G. den Daas I et al. Naunyn Schmiedebergs Arch Pharmacol 655-659					
		8/3/1989 Abstract of "Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437" P.A. Loschmann et al. Eur J. Pharmacol 373-380					
EXAMINER Isis A. D. Ghali				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							